Ackley J et al. Keeping myeloma in check: The past, present and future of immunotherapy in multiple myeloma. Cancers (Basel) 2021;13(19):4787. Abstract

Casey M et al. Are pivotal clinical trials for drugs approved for leukemias and multiple myeloma representative of the population at risk? J Clin Oncol 2022;40(32):3719-29. Abstract

Chandhok NS, Sekeres MA. Just and equitable enrollment to pivotal clinical trials in hematologic malignancies. J Clin Oncol 2022;40(32):3677-80. Abstract

Hurvitz SA. DESTINY-changing results for advanced breast cancer. N Engl J Med 2022;387(1):75-6. Abstract

Mato AR et al. Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in previously treated CLL/SLL: Updated results from the phase 1/2 BRUIN study. EHA 2022;Abstract S147.

Modi S et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med 2022;387(1):9-20. Abstract

Modi S et al. Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Results of DESTINY-Breast04, a randomized, phase 3 study. ASCO 2022;Abstract LBA3.

Morris MJ et al. Phase III study of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer (VISION). ASCO 2021;Abstract LBA4.

Reck M et al. Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score ≥ 50. J Clin Oncol 2021;39(21):2339-49. Abstract